Therapy Clinical Trials in Shanghai
34 recruitingShanghai, China
Showing 1–20 of 34 trials
Recruiting
Phase 3
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568
Recruiting
Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled59 locationsNCT06535607
Recruiting
Phase 3
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Gastric Cancer (GC)Adjuvant ChemotherapyOxaliplatin+2 more
Ruijin Hospital387 enrolled5 locationsNCT07366528
Recruiting
Phase 3
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Breast CancerAdjuvant Therapy
Fudan University1,903 enrolled1 locationNCT07019363
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Melanoma (10hospital)
Advanced MelanomaTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05098184
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Breast CancerAdvanced Breast CancerTreatment Side Effects+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05142475
Recruiting
Phase 2
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting
Not Applicable
Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
Breast CancerProton Therapy
Shanghai Proton and Heavy Ion Center312 enrolled1 locationNCT07135661
Recruiting
Phase 2
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
Perioperative ImmunotherapyLimited Stage Lung Small Cell CarcinomaResectable Small Cell Lung Cancer
Fudan University37 enrolled1 locationNCT07109401
Recruiting
Phase 2
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Colo-rectal CancerBevacizumabThird-line and Beyond Therapy+1 more
Ruijin Hospital50 enrolled2 locationsNCT07085169
Recruiting
Not Applicable
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University36 enrolled1 locationNCT06856200
Recruiting
Not Applicable
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
Breast CancerAromatase InhibitorsEndocrine Therapy+1 more
Fudan University80 enrolled1 locationNCT06642948
Recruiting
The Study on the Mechanism of Radiotherapy-elicited Immune Response
RadiotherapyEsophageal Carcinoma Salivary Gland Type
Fudan University200 enrolled1 locationNCT06393140
Recruiting
Phase 2
Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276
Recruiting
Phase 2
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Gastric CancerImmunotherapyToripalimab+1 more
Shanghai Changzheng Hospital24 enrolled1 locationNCT04278222
Recruiting
Phase 3
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Esophageal Squamous Cell CarcinomaOligometastatic DiseaseRadiotherapy
Fudan University354 enrolled1 locationNCT06190782
Recruiting
Phase 1Phase 2
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Locally Advanced Cervical CarcinomaImmunotherapyConcurrent Chemoradiotherapy
RenJi Hospital20 enrolled1 locationNCT06391190
Recruiting
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
Locally Advanced Cervical CarcinomaImmunotherapyConcurrent Chemoradiotherapy
RenJi Hospital20 enrolled1 locationNCT06378840
Recruiting
Phase 2
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
Serplulimab,Gastric Cancer, Adjuvant Therapy
RenJi Hospital70 enrolled1 locationNCT05769725
Recruiting
Phase 2
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Chemotherapy, Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China460 enrolled1 locationNCT03351842